2-Year Phase 3 Study Of CP-690,550 In Patients With Active Rheumatoid Arthritis On Background Methotrexate - NCT00847613-21224 (Clinical Trial 363754)
Permalink: http://www.ClinicalConnection.com/exp/ExpandedPatientViewStudy363754.aspx
|
** Please review additional "Nearby Studies" on right ----->
|
|
 |
 |
|
| City: |
|
Baltimore |
|
State:
|
|
MD |
| Zip Code: |
|
21224 |
| Conditions: |
|
Arthritis, Rheumatoid |
| Purpose: |
|
This study is designed to provide safety and efficacy data to support the development of
CP-690,550 in patients with moderate to severe rheumatoid arthritis on background of
methotrexate.
|
| Study summary: |
|
|
| Criteria: |
|
Inclusion Criteria:
- Adults with moderate to severe rheumatoid arthritis on a stable dose of methotrexate
Exclusion Criteria:
- Pregnancy, severe acute or chronic medical conditions, including serious infections
or clinically significant laboratory abnormalities. |
|
|
|
| Study is available at: |
|
Pfizer Investigational Site
Baltimore, MD 21224
United States
Primary Contact:
Pfizer CT.gov Call Center
Phone: 1-800-718-1021 |
|
|
If you are interested in this clinical trial please use the contact information above. If you would like to get additional information about this clinical trial please visit ClinicalTrials.gov.
|
| Trials Alerts: |
|
If you would like to be
notified of new clinical trials as they become available please
register for a free account.
|
|
| Data Source: |
|
ClinicalTrials.gov |
| Date Processed: |
|
November 16, 2009 |
Modifications to
this listing: |
|
Only selected fields are shown, please use the link
above to view all information about this clinical trial. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
| |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Clinical trials are medical research studies designed to test the safety and/or
effectiveness of new drugs, devices, or treatments in humans. These studies are
conducted worldwide for a range of conditions and illnesses. Learn more about
clinical research and participating in a study at
About Clinical Trials.
|
|
|
|
|